Depot antipsychotics

Antipsychotic Drugs: Pharmacology, Side Effects and Abuse Prevention

Volumn , Issue , 2013, Pages 79-105

  Warikoo, Nisha ^a   Schwartz, Thomas L ^a   Citrome, Leslie ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883171286     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (156)

1. Byerly, M., Nakonezny, P., Lescouflair, E. Antipsychotic medication adherence in schizophrenia. Psychiatr. Clin. North Am. 2007;30:427-452.
2. Wyatt, R. J. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 1991;17:325-351.
3. Lieberman, J. A., Sheitman, B., Chakos, M., et al. The development of treatment resistance in patients with schizophrenia:a clinical and pathophysiologic perspective. J. Clin. Psychopharmacol. 1998;18:20S-24S.
4. Fenton, W. S., Blyler, C. R., Heinssen, R. K. Determinants of medication compliance in schizophrenia:empirical and clinical findings. Schizophr. Bull. 1997;23:637-51.
5. Olfson, M., Mechanic, D., Hansell, S., et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr. Serv. 2000;51:216-22.
6. Weiden, P. J., Olfson, M. Cost of relapse in schizophrenia. Schizophr. Bull. 1995;21:419-429.
7. Ayuso-Gutierrez, J. L., del Rio Vega, J. M. Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res. 1997;28:199-206.
8. Stefen, L., Stephen, H. Epidemiology, clinical consequences and psychosocial treatment of nonadherence in schizophrenia. J. Clin. Psychiatry 2006;67:S3-8.
9. Steadman, H. J., Mulvey, E. P., Monahan, J., et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch. Gen. Psychiatry 1998;55:393-401.
10. Swartz, M. S., Swanson, J. W., Hiday, V. A., et al. Taking the wrong drugs:the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc. Psychiatry Psychiatr. Epidemiol. 1998;33:S75-S80.
11. Johnson, D. A. W., Pasterski, J. M., Ludlow, J. M., et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients:drug and social consequences. Acta Psychiatr. Scand. 1983;67:339-352.
12. Fenton, W. Schizophrenia:Integrative treatment and functional outcomes. Sadock, B. J., Sadock, V. A. Comprehensive textbook of psychiatry 8th ed. Philadelphia:Williams and Wilkins;2004.
13. Velligan, D. I., Wang, M., Diamond, P., et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr. Serv. 2007;58:1187-1192.
14. Velligan, D. I., Lam, Y. W., Glahn, D. C., et al. Defining and assessing adherence to oral antipsychotics:a review of the literature. Schizophr. Bull. 2006;32:724-742.
15. Harrison, T. S., Goa, K. L. Long-acting risperidone:a review of its use in schizophrenia. CNS Drugs 2004;18:113-132.
16. Johnson and Johnson, 2009. FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia. Press release, 31 July 2009. Available at:http://www.jnj.com/connect/news/all/20090731_153000. Accessed 2 September 2009.
17. Citrome, L. Olanzapine pamoate:a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second generation antipsychotic. Int. J. Clin. Pract. 2009;63:140-150.
18. Otsuka Pharmaceutical Development and Commercialization, Inc., 2008. Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Schizophrenia (ASPIRE). Registry entry, 7 Aug 2008. Available at:http://clinicaltrials.gov/ct2/show/NCT00731549. Accessed 31 Oct. 2008.
19. Citrome, L. Iloperidone for schizophrenia:a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int. J. Clin. Pract. 2009;63:1237-1248.
20. Levine, J., Schooler, N. R., Cassano, G. B. The role of depot neuroleptics in the treatment of schizophrenic patients. Psychol. Med. 1979;9:383-386.
21. Barnes, T. R., Curson, D. A. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf. 1994;10:464-479.
22. Citrome, L., Jaffe, A., Levine, J. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Schizophr. Res. 2010;119:153-159.
23. Leucht, C., Heres, S., Kane, J. M., et al. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011;127:83-92.
24. Tiihonen, J., Haukka, J., Taylor, M., et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 2011;168:603-609.
25. Peng, X., Ascher-Svanum, H., Faries, D., et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon. Outcomes Res. 2011;3:9-14.
26. Davis, J. M., Metalon, L., Watanabe, M. D. Depot antipsychotic drugs:place in therapy. Drugs 1994;47:741-773.
27. Mentschel. 156th mtg of APA;San Francisco, May 17-22, 2003. Abstract book, page 71.
28. Adams, C. E., Fenton, M. K., Quraishi, S., et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 2001;179:290-299.
29. Weiden, P., Rapkin, B., Zygmunt, A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr. Serv. 1995;46:1049-1054.
30. Barnes, T. R. Depot antipsychotic drugs and prevention of psychotic relapse. Clin. Neuropharmacol. 1991;14:S1-6.
31. Pollack, S. L., Tourlentes, T. T., Zocchi, A. F. Clinical Trial of Fluphenazine Enanthate--a Long-Acting Injectable Tranquilizer. Am. J. Psychiatry 1964;121:73-74.
32. Kane, J. M., Aguglia, E., Altamura, A. C., et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol. 1998;8:55-66.
33. Pandarakalam, J. P. Atypical and conventional depot medications. Hosp. Med. 2003;64:658-663.
34. Bucci, L., Fuchs, M., Simeon, J., et al. Depot fluphenazine in the treatment of psychosis in a community mental health clinic. Dis. Nerv. Syst. 1970;31:28-31.
35. Caffey, E. M. Jr, Diamond, L. S., Frank, T. V., et al. Discontinuation Or Reduction of Chemotherapy in Chronic Schizophrenics. J. Chronic Dis. 1964;17:347-358.
36. Ereshefsky, L., Saklad, S. R., Jann, M. W., et al.Future of depot neuroleptic therapy:pharmacokinetic and pharmacodynamic approaches. J. Clin. Psychiatry 1984;45:50-59.
37. Marder, S. R., Van Putten, T., Aravagiri, M., et al. Fluphenazine plasma levels and clinical response. Psychopharmacol. Bull. 1990;26:256-259.
38. Jann, M. W., Ereshefsky, L., Saklad, S. R. Clinical pharmacokinetics of the depot antipsychotics. Clin. Pharmacokinet. 1985;10:315-333.
39. Wiles, D. H., Gelder, M. G. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Adv. Biochem. Psychopharmacol. 1980;24:599-602.
40. Wistedt, B., Wiles, D., Kolakowska, T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 198;23:1163.
41. Amdisen, A., Thomsen, N. J. Drug levels after withdrawal of long-term depot neuroleptics. Lancet 1981;1:1425.
42. Ereshefsky, L., Jann, M. W., Saklad, S. R., et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol. Psychiatry 1985;20:329-332.
43. Kane, J. M., Rifkin, A., Woerner, M., et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch. Gen. Psychiatry 1983;40:893-896.
44. Hogarty, G. E., McEvoy, J. P., Munetz, M., et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch. Gen. Psychiatry 1988;45:797-805.
45. Schooler, N. R., Keith, S. J., Severe, J. B., et al. Relapse and rehospitalization during maintenance treatment of schizophrenia:the effects of dose reduction and family treatment. Arch. Gen. Psychiatry 1997;54:453-463.
46. Kane, J. M., Woerner, M., Sarantakos, S.:Depot neuroleptics:a comparative review of standard, intermediate, and low-dose regimens. J. Clin. Psychiatry 1986;47:30-33.
47. Schooler, N. R., Levine, J. The initiation of long-term pharmacotherapy in schizophrenia:dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatr. Neuropsychopharmakol. 1976;9:159-169.
48. Hirsch, S. R. The interaction between depot-phenothiazines and the social and clinical manifestations of behavior in patients with stabilised chronic schizophrenia. In:Van Praag, H. M. editor(s). On the origin of schizophrenic psychoses. De Erven. Bohn BV, 1975:209-222.
49. Odejide, O. A., Aderounmu, A. F. Double-blind placebo substitution:Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology 1982;43:195-206.
50. Rifkin, A., Quitkin, F., Kane, J., et al. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacol. Bull. 1977;13:40-50.
51. David, A., Adams, C. E., Eisenbruch, M., et al. Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database Syst. Rev. 2005;(1)(1):CD000307.
52. Jolley, A. G., Hirsch, S. R., Morrison, E., et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients:clinical and social outcome at two years. Brit. Med. J. 1990;301:837-842.
53. Barnes, T. R. E., Milavic, G., Curson, D. A., et al. Use of the social behaviour assessment schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients:pimozide versus fluphenazine. Soc. Psychiatr. 1983;18:193-9.
54. Curry, S. H., Adamson, L. Double-blind trial of fluphenazine decanoate. Lancet 1972;2:543-4.
55. Fallon, I., Watt, D. C., Shepherd, M. The social outcome of patients in a trial of longterm continuation therapy in schizophrenia:pimozide vs fluphenazine. Psychol. Med. 1978;8:265-74.
56. Simon, P., Fermanian, J., Ginestet, D., et al. Standard and long-acting depot neuroleptics in chronic schizophrenics. Arc. Gen. Psychiat. 1978;35:893-7.
57. Shu, L. Double-blind study of domestic penfluridol and fluphenazine decanoate. Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1983;16:141-5. Chinese. No abstract available.
58. Schooler, N. R., Levine, J., Severe, J. B. Depot fluphenazine in the prevention of relapse in schizophrenia:Evaluation of a Treatment Regimen. Psychopharmacol. Bull. 1979;15:44-7.
59. Chouinard, G., Annable, L., Campbell, W., et al. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacol. Bull. 1984;20:108-9.
60. Cookson, J. C., Kennedy, N. M., Gribbon, D. Weight gain and prolactin levels in patients on long-term antipsychotic medication:a double-blind comparative trial of haloperidol decanoate and fluphenazine decanaote. International Clin. Psychopharmacol. 1986;1:41-51.
61. Dencker, S. J., Frankenberg, K., Lepp, M., et al. Three years' maintenance neuroleptic treatment in schizophrenia-before and beyond. Act. Psychia. Scand. 1978;57:103-114.
62. Feng, L. Double blind controlled trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenia. Chinese Journal of Nervous and Mental Disorders 1990;16:299.
63. Frangos, H., Zississ, N. P., Leontopoulos, I., et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Act. Psychiat. Scand. 1978;57:436-446.
64. Leong, O. K., Wong, K. E., Tay, W. K., et al. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal 1989;30:536-540.
65. McKane, J. P., Robinson, A. D. T., Wiles, D. H., et al. Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Brit. J. Psych. 1987;151:333-336.
66. McLaren, S., Cookson, J. C., Silverstone, T. Postive and negative symptoms, depression and social disability in chronic schizophrenia:a comparative trial of bromoperidol and fluphenazine decanoates. Int. Clin. Psychopharm. 1992;7:67-72.
67. Schlosberg, A., Shadmi, M. A comparative controlled study of two long-acting phenothiazines:Pipothiazine palmitate and fluphenazine decanoate. Curr. Ther. Res. 1978;23:642-54.
68. Asarnow, R. E., Marder, S. R., Mintz, J., et al. Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing skills. Arch. Gen. Psychiat. 1988;45:822-827.
69. Marder, S. R., Van Putten, T., Mintz, J., et al. Low and conventional dose maintenance therapy with fluphenazine decanoate. Arch. Gen. Psychiat. 1987;44:518-521.
70. Marder, S. R., Van Putten, T., Mintz, J., McKenzie, J., Lebell, M., Faltico, G., May, P. R. A. Costs and benefits of two doses of fluphenazine. Arch. Gen. Psychiat. 1984;41:1025-1029.
71. McClelland, H., Farquharson, R. G., Leyburn, P., et al. Furness, J. A., Schiff, A. A. Very high dose fluphenazine decanoate. Arch. Gen. Psychiat. 1976;33:1435-1449.
72. Kreisman, D., Blumenthal, R., Borenstein, M., et al. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics:the family's view. Psychiatry 1988;51:3-13.
73. Chien, C. P., Cole, J. O. Depot phenothiazine treatment in acute psychosis:A sequential comparative clinical study. Am. J. Psych. 1973;130:13-17.
74. Albert, J. M., Elie, R., Cooper, S. F. Long term double-blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Curr. Ther. Res. 1980;27:897-907.
75. Chouinard, G., Annable, L., Kropsky, M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. J. Clin. Psychopharmacol. 1978;148-154.
76. Malm, U., Perris, C., Rapp, W., et al. A Multicentre Trial of Flusperilene and Fluphenazine Enanthate in Chronic Schizophrenic syndromes. Acta Psychiat. Scand. Supplementum 1974;249:94-116.
77. Donlon, P. T., Rada, R. T., Arora, K. K. Depression and the reintegration phase of acute schizophrenia. Am. J. Psych. 1976;133:1265-8.
78. McCreadie, R. G., McKane, J. P., Mackie, M. Weekly pimozide versus fluphenazine decanoate in schizophrenic out and day patients. Brit. J. Psych. 1983;143:97-98.
79. McCreadie, R. G., McKane, J. P., Robinson, A. D. T., et al. Depot neuroleptics as maintenance therapy in chronic schizophrenic in-patients. Inter. Clin. Psychopharmacol. 1986;1:13-14.
80. Adamson, L., Currey, S. H., Bridges, P. K., Firestone, A. F., Lavin, N. I., Lewis, D. M., Watson, R. D., Xavier, C. M., Anderson, J. A. Fluphenazine decanoate trial in chronic inpatient schizophrenics failing to absorb oral chlorpromazine. Dis. Nervous. System 1973;34:181-191.
81. McCreadie, R., Mackie, M., Morrison, D., Kidd, J. Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. Brit. J. Psych. 1982;140:280-286.
82. Knights, A., Okasha, M. S., Salih, M. A., et al Depressive and extrapyramidal symptoms and clinical effects:a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. Br. J. Psychiatry 1979;135:515-523.
83. Van Praag, H. M., Dols, L. C. Fluphenazine enanthate and fluphenazine decanoate:a comparison of their duration of action and motor side effects. Am. J. Psychiatry 1973;130:801-804.
84. Kurland, A. A., Dim, B. M., Olssen, J. E. The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics. Dis. Nervous System 1970;31:18-23.
85. Beresford, R., Ward, A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987;33:31-49.
86. Forsman, A., Ohman, R. Studies on serum protein binding of haloperidol. Curr. Ther. Res. Clin. Exp. 1977;21:245-255.
87. Reyntigens, A. J., Heykants, J. J., Woestenborghs, R. J et al. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. Int. Pharmacopsychiatry 1982;17:238-246.
88. Viukari, M., Salo, H., Lamminsivu, U., et al. Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatr. Scand. 1982;65:301-308.
89. Hemstrom, C. A., Evans, R. L., Lobeck, F. G. Haloperidol decanoate:a depot antipsychotic. Drug Intell Clin. Pharm. 1988;22:290-295.
90. Quraishi, S., David, A. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst. Rev. 2000;(2):CD001361.
91. Eklund, K., Forsman, A. Minimal effective dose and relapse-double blind trial:haloperidol decanoate versus placebo. Clin. Neuropharmac. 1991;14:7-15.
92. Zissis, N. P., Psaias, M., Lykctsos, G. Haloperidol decanoate, a new long actiing antipsychotic in chronic schizophrenics:Double blind comparison with placebo. Curr. Ther. Res. 1982;31:650-655.
93. Zuardi, A. W., Giampietro, A. C., Grassi, E. R., et al. Double-blind comparison between two forms of haloperidol:an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. Curr. Ther. Res. 1983;34:253-261.
94. Bechelli, L. P. C., Lecco, M. C., Pontes, M. C. A double-blind trial of haloperidol decanoate and pipothiazine palmitate in the maintenance treatment of schizophrenics in a public out-patient clinic. Curr. Ther. Res. 1985;37:662-71.
95. Guy, W. Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology. Washington, DC:US Government Printing Office, 1976. :National Institute of Mental Health Publication No. 76-338]
96. Wistedt, B., Koskinen, T., Thelander, S., et al. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia:a double-blind multicentre study. Acta Psychiatr. Scand. 1991;84:14-21.
97. Ehret, M. J., Fuller, M. A. Long-acting injectable risperidone. Ann. Pharmacother. 2004;38 :2122-2127.
98. Lasser, R. A., Ramstack, J. M., Grandolfi, G. M., et al. Long-acting risperidone (Risperidone Microsphere):manufacture using Medisorb microsphere, technology, pharmacokinetics and injection-site assessments. Presented at the 155th Annual Meeting of the American Psychiatric Association 2002, May 18-23, 2002;Philadelphia, PA. US.
99. MIMS Australia. Risperdal Consta. MIMS online. 2009. Accessed May 21, 2009]. Available from:http://www.mims.com.au/
100. Volkow, N. D., Wang, G. J., Fowler, J. S., et al. Parallel loss of presynaptic and post synaptic dopamine markers in normal ageing. Ann. Neurol. 1998;44:143-147.
101. Eerdekens, M., Van Hove, I., Remmerie, B., et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004;70:91-100.
102. Janssen Pharmaceuticals Inc. Risperidal consta (risperidone long-acting injection):prescribing information online]. Available from URL:http://www.janssencns.com/risperdal-prescribing-information. Revised 12/2012.
103. Singh, D., O'Connor, D. W. Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia. Clin. Interv. Aging 2009;4:351-355.
104. Chue, P. Risperidone long-acting injection. Expert Rev. Neurother. 2003 Jul.;3:435-446.
105. Kane, J. M., Eerdekens, M., Lindenmayer, J. P. Long-acting injectable risperidone:efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003;160:1125-1132.
106. Fleischhacker, W., Eerdekens, M., Karcher, K. Treatment of schizophrenia with longacting injectable risperidone:a 12 month evaluation of the first long-acting 2nd generation antipsychotic. J. Clin. Psychiatry 2003:64:1250-1257.
107. Van, O. S. J., Bossie, C., Lasser, R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int. Clin. Psychopharmacol. 2004;19:229-232.
108. Lindenmayer, J. P., Eerdekens, E., Berry, S. A., Eerdekens, M. Safety and efficacy of long-acting risperidone in schizophrenia:a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J. Clin. Psychiatry 2004;65:1084-1089.
109. Gastpar, M., Masiak, M., Latif, M. A. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J. Psychopharmacol. 2005;19:32-38.
110. Lasser, R., Bossie, C., Gharabawi, G., et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatry 2004;19:219-225.
111. Turner, M., Eerdekens, E., Jacko, M., et al. Long-acting injectable risperidone:safety and efficacy in stable patients switched from conventional depot antipsychotics. Int. Clin. Psychopharmacol. 2004;19:241-249.
112. Lasser, R., Bossie, C., Gharabawi, G., et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone:a 12-month open trial. Int. J. Neuropsychopharmacol. 2005;8:1-12.
113. Marinis, T. D., Saleem, P. T., Glue, P. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007;40:257-263.
114. Schmauss, M., Sacchetti, E., Kahn, J. P., et al. Efficacy and safety of risperidone longacting injectable in stable psychotic patients previously treated with oral risperidone. Int. Clin. Psychopharmacol. 2007;22:85-92.
115. Hawley, C., Turner, M., Latif, M. A., et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone:reasons for switching and safety. Hum. Psychopharmacol. 2010;25:37-46.
116. Lloyd, K., Latif, M. A., Simpson, S., et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone:efficacy, quality of life and functional outcome. Hum. Psychopharmacol. 2010;25:243-252.
117. Chue, P., Eerdekens, M., Augustyns, I. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 2005;15:111-117.
118. Bai, Y. M., Chen, T. T., Wu, B. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients:12-week randomized, single-blind study. Pharmacopsychiatry 2006;39:135-141.
119. Möller, H., Llorca, P. M., Sachetti, E., et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 2005;20:121-130.
120. Pecenak, J., Tuma, I., de Groot-Stam, L. Improvement in personal and social functioning in schizophrenia patients treated with risperidone long-acting injectable:6-month results from E-STAR. Presented at:The American Psychiatric Association Annual Meeting. Washington, DC, US, 3-8 May 2008.
121. Canas, F., Moller, H. J. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia:safety and tolerability review. Expert Opin. Drug Saf. 2010;9:683-697.
122. Möller, H. J. Long-acting risperidone:focus on safety. Clin. Ther. 2006;28:633-651.
123. Kapur, S., Zipursky, R. B., Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 1999;156:286-293
124. Kapur, S., Zipursky, R., Jones, C., et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects:a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000;157:514-520.
125. Taylor, D. M., Fischetti, C., Sparshatt, A. Risperidone long-acting injection:a prospective 3-year analysis of its use in clinical practice. J. Clin. Psychiatry 2009;70:196-200.
126. Martinez, G., Schreiner, A. Risperidone long-acting injectable and olanzapine pamoate:review of short-and long-term safety data. Presented at the 9th World Federation of Societies of Biological Psychiatry;29 June--2 July 2009;Paris, France.
127. Yang, L. P., Plosker, G. L. Paliperidone extended release. CNS Drugs 2007;21:417-425.
128. Samtani, M. N., Vermeulen, A., Stuyckens, K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia:a novel oncemonthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 2009;48:585-600.
129. Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Invega Sustenna (paliperidone palmitate) Extended-Release Injectable Suspension. Accessed at URL http://www.janssencns.com/sustenna-prescribing-information ( October 2011).
130. Cleton, A., Rossenu, S., Hough, D., et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles abstract no. PI-74]. Clin. Pharmacol. Ther. 2008 Mar.;83 Suppl. 1:S31. Plus poster presented at the American Society for Clinical Pharmacology and Therapeutics;2008 Apr. 2-5;Orlando (FL).
131. Cleton, A., Rossenu, S., Hough, D., et al. Evaluation of the pharmacokinetic profile of gluteal versus deltoid intramuscular injections of paliperidone palmitate 100mg equivalent in patients with schizophrenia abstract no. PI-75]. Clin. Pharmacol. Ther. 2008 Mar.;83 Suppl. 1:S31. Plus poster presented at the American Society for Clinical Pharmacology and Therapeutics;2008 Apr. 2-5;Orlando (FL).
132. Hough, D., Lindenmayer, J.-P., Gopal, S. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009;33:1022-31.
133. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia:a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010;25(5):247-256.
134. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010 ;35(10):2072-2082.
135. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010 Jun;13(5):635-647.
136. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30(3):235-244.
137. Fleischhacker, W. W., Gopal, S., Lane, R., et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int. J. Neuropsychopharmacol. 2011;22:1-12.
138. Pandina, G., Lane, R., Gopal, S., et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011;15;35:218-226.
139. Li, H., Rui, Q., Ning, X., et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011;35:1002-1008.
140. Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010 Jan;64(2):216-239.
141. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia:a randomized, double-blind, placebo-controlled study. Schizophr Res 2010 Feb;116(2-3):107-117.
142. Kurtz, D., Bergstrom, R., McDonnell, D. P., et al. Pharmacokinetics (PK) of multiple doses of olanzapine long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ) in stabilized patients with schizophrenia. Biol. Psychiatry 2008;63:abstract 909.
143. Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., et al. Olanzapine, pharmacokinetic and pharmacodynamic profile. Clin. Pharmacokinet. 1999;37:177-193.
144. Gulliver, A., McDonnell, D. P., Kryzhanovskaya, L. A., et al. Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular longacting injection versus olanzapine oral formulation abstract]. Int. J. Neuropsychopharmacol. 2008;11:152.
145. Gulliver, A., Detke, H. C., McDonnell, D. P., et al. Olanzapine long-acting injection:Pharmacokinetic and dose correspondence data relative to oral Olanzapine abstract]. Int. J. Neuropsychopharmacol. 2008;11:152-153.
146. Eli Lilly and Company. Zyprexa Olanzapine Pamoate (OP) Depot. Accessed at URL http://pi.lilly.com/us/zyprexa_relprevv.pdf (revised 07/2011).
147. Lauriello, J., Lambert, T., Andersen, S., et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J. Clin. Psychiatry 2008;69:790-799.
148. Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D. Y., Bergstrom, R. F., McDonnell, D. Olanzapine long-acting injection:a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am. J. Psychiatry 2010;167:181-189.
149. Detke, H. C., Weiden, P. J., Lambert, T. Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients:a 2-year, randomized, open-label study. Eur. Neuropsychopharmacol. 2010;20 (Suppl. 3):464.
150. McDonnell, D. P., Detke, H. C., Bergstrom, R. F. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II:investigations of mechanism. BMC Psychiatry 2010;10:45.
151. Remington, G. J., Adams, M. E. Depot neuroleptic therapy:clinical considerations. Can. J. Psychiatry 1995;40:S5-11.
152. Heres, S., Hamann, J., Kissling, W., et al. Attitudes of psychiatrists toward antipsychotic depot medication. J. Clin. Psychiatry 2006;67:1948-1953.
153. Glazer, W. M., Kane, J. M. Depot neuroleptic therapy:An underutilized treatment option. J. Clin. Psychiatry 1992;53:426-433.
154. Shi, L., Ascher-Svanum, H., Zhu, B., et al. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr. Serv. 2007;58:482-488.
155. Citrome, L., Jaffe, A., Levine, J. Datapoints:depot antipsychotic use in New York State hospitals, 1994 to 2009. Psychiatr. Serv. 2010;61:9.
156. Waddell, L., Taylor, M. Attitudes of patients and mental health staff to antipsychotic long-acting injections:systematic review. Br. J. Psychiatry Suppl. 2009 ;52:S43-50.